Tramadol Co-Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control.
Gene–drug pair / mechanism
Both tramadol and oxycodone rely on CYP2D6 bioactivation, which limits the expected benefit of a dual mechanism of action; the sensitivity analysis restricted to CYP2D6 normal metabolizers tests this hypothesis.
Summary
This secondary analysis of the multicenter IGNITE ADOPT-PGx pragmatic trial compared, after elective surgery, oxycodone alone (n = 317) with tramadol + oxycodone (n = 96), and hydrocodone alone (n = 563) with tramadol + hydrocodone (n = 42). Co-primary outcomes were cumulative morphine milligram equivalents (MME) consumed over the 10 postoperative days and a composite day-10 pain score (range 3 to 15), with inverse probability of treatment weighting to adjust for demographics, comorbidities and concomitant analgesics. Oxycodone + tramadol was associated with higher opioid consumption (adjusted mean MME 205.2 vs 122.5; P < 0.0001) and lower mobility, without meaningful difference in pain score (9.6 vs 9.4; P = 0.41). Findings were similar for hydrocodone and consistent across sensitivity analyses, including the one restricted to CYP2D6 normal metabolizers, and in the total knee arthroplasty subgroup.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
This is the kind of result that transfers directly to the clinic: adding tramadol to a strong opioid after surgery increases opioid burden by more than 80 MME with no measurable analgesic gain, dismantling a very common prescribing reflex. The pharmacogenetic argument is indirect but elegant: the effect persists among CYP2D6 normal metabolizers alone, which rules out the convenient explanation of impaired bioactivation and points to the combination itself. The caveat is the marked group imbalance, with only 42 patients on tramadol + hydrocodone, and the observational nature of the comparison despite weighting: residual confounding by indication, with the most painful patients receiving the combination, remains plausible.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 3/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 8/10
Keywords
More articles on CYP2D6
Every Wednesday · Annotated selection · Free · Unsubscribe anytime